Sullivan stated that when patients discontinue GLP-1 therapy weight regain occurs in the vast majority of patients, and the metabolic benefits are lost. DMR uses hydrothermal ablation to target and remove the duodenal mucosa, which is a known site for metabolic dysfunction
The recent FDA clarifications and ensuing legal battles underscore a fundamental tension: the need to balance patient safety with market innovation
Weeks 13-24: Maximum Velocity Side effects have largely resolved while appetite suppression remains strong
Regarding compounded GLP-1 drugs, patient safety advocates point to exemptions from standard product labeling requirements, which leave consumers without information on side effects, contraindications, and possible adverse effects and opens the door for marketers to tout the benefits of compounded GLP-1s without disclosing the risks
Clinical trial data showed that 5-6% of participants experienced hair loss at higher doses, compared to about 1% taking placebo